Tanvex BioPharma Inc
TWSE:6541

Watchlist Manager
Tanvex BioPharma Inc Logo
Tanvex BioPharma Inc
TWSE:6541
Watchlist
Price: 68.1 TWD -2.44% Market Closed
Market Cap: 11.2B TWD
Have any thoughts about
Tanvex BioPharma Inc?
Write Note

Intrinsic Value

Tanvex BioPharma Inc's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

The intrinsic value of one Tanvex BioPharma Inc stock under the Base Case scenario is 1.61 TWD. Compared to the current market price of 68.1 TWD, Tanvex BioPharma Inc is Overvalued by 98%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

Intrinsic Value
1.61 TWD
Overvaluation 98%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Tanvex BioPharma Inc

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for Tanvex BioPharma Inc cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about Tanvex BioPharma Inc?
Bearish
Neutral
Bullish

Fundamental Analysis

Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Investment Journal
AI Assistant
AI Assistant
Ask me anything about Tanvex BioPharma Inc

Provide an overview of the primary business activities
of Tanvex BioPharma Inc.

What unique competitive advantages
does Tanvex BioPharma Inc hold over its rivals?

What risks and challenges
does Tanvex BioPharma Inc face in the near future?

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Tanvex BioPharma Inc.

Provide P/S
for Tanvex BioPharma Inc.

Provide P/E
for Tanvex BioPharma Inc.

Provide P/OCF
for Tanvex BioPharma Inc.

Provide P/FCFE
for Tanvex BioPharma Inc.

Provide P/B
for Tanvex BioPharma Inc.

Provide EV/S
for Tanvex BioPharma Inc.

Provide EV/GP
for Tanvex BioPharma Inc.

Provide EV/EBITDA
for Tanvex BioPharma Inc.

Provide EV/EBIT
for Tanvex BioPharma Inc.

Provide EV/OCF
for Tanvex BioPharma Inc.

Provide EV/FCFF
for Tanvex BioPharma Inc.

Provide EV/IC
for Tanvex BioPharma Inc.

Show me price targets
for Tanvex BioPharma Inc made by professional analysts.

What are the Revenue projections
for Tanvex BioPharma Inc?

How accurate were the past Revenue estimates
for Tanvex BioPharma Inc?

What are the Net Income projections
for Tanvex BioPharma Inc?

How accurate were the past Net Income estimates
for Tanvex BioPharma Inc?

What are the EPS projections
for Tanvex BioPharma Inc?

How accurate were the past EPS estimates
for Tanvex BioPharma Inc?

What are the EBIT projections
for Tanvex BioPharma Inc?

How accurate were the past EBIT estimates
for Tanvex BioPharma Inc?

Compare the revenue forecasts
for Tanvex BioPharma Inc with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Tanvex BioPharma Inc and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Tanvex BioPharma Inc against its competitors.

Analyze the profit margins
(gross, operating, and net) of Tanvex BioPharma Inc compared to its peers.

Compare the P/E ratios
of Tanvex BioPharma Inc against its peers.

Discuss the investment returns and shareholder value creation
comparing Tanvex BioPharma Inc with its peers.

Analyze the financial leverage
of Tanvex BioPharma Inc compared to its main competitors.

Show all profitability ratios
for Tanvex BioPharma Inc.

Provide ROE
for Tanvex BioPharma Inc.

Provide ROA
for Tanvex BioPharma Inc.

Provide ROIC
for Tanvex BioPharma Inc.

Provide ROCE
for Tanvex BioPharma Inc.

Provide Gross Margin
for Tanvex BioPharma Inc.

Provide Operating Margin
for Tanvex BioPharma Inc.

Provide Net Margin
for Tanvex BioPharma Inc.

Provide FCF Margin
for Tanvex BioPharma Inc.

Show all solvency ratios
for Tanvex BioPharma Inc.

Provide D/E Ratio
for Tanvex BioPharma Inc.

Provide D/A Ratio
for Tanvex BioPharma Inc.

Provide Interest Coverage Ratio
for Tanvex BioPharma Inc.

Provide Altman Z-Score Ratio
for Tanvex BioPharma Inc.

Provide Quick Ratio
for Tanvex BioPharma Inc.

Provide Current Ratio
for Tanvex BioPharma Inc.

Provide Cash Ratio
for Tanvex BioPharma Inc.

What is the historical Revenue growth
over the last 5 years for Tanvex BioPharma Inc?

What is the historical Net Income growth
over the last 5 years for Tanvex BioPharma Inc?

What is the current Free Cash Flow
of Tanvex BioPharma Inc?

Discuss the annual earnings per share (EPS)
trend over the past five years for Tanvex BioPharma Inc.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Tanvex BioPharma Inc

Current Assets 1.2B
Cash & Short-Term Investments 1B
Receivables 19.7m
Other Current Assets 159m
Non-Current Assets 2.2B
Long-Term Investments 213.8m
PP&E 1.9B
Intangibles 4.8m
Other Non-Current Assets 24.2m
Current Liabilities 335.3m
Accrued Liabilities 109.6m
Other Current Liabilities 225.7m
Non-Current Liabilities 1.6B
Long-Term Debt 1.6B
Other Non-Current Liabilities 8.1m
Efficiency

Earnings Waterfall
Tanvex BioPharma Inc

Revenue
34.6m TWD
Cost of Revenue
-26.2m TWD
Gross Profit
8.4m TWD
Operating Expenses
-1.8B TWD
Operating Income
-1.8B TWD
Other Expenses
-14.6m TWD
Net Income
-1.8B TWD

Free Cash Flow Analysis
Tanvex BioPharma Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
Fundamental Scores

Profitability Score
Profitability Due Diligence

Tanvex BioPharma Inc's profitability score is 23/100. The higher the profitability score, the more profitable the company is.

Exceptional 3-Years Revenue Growth
ROIC is Increasing
Positive Gross Profit
Negative 1-Year Revenue Growth
23/100
Profitability
Score

Tanvex BioPharma Inc's profitability score is 23/100. The higher the profitability score, the more profitable the company is.

Solvency Score
Solvency Due Diligence

Tanvex BioPharma Inc's solvency score is 37/100. The higher the solvency score, the more solvent the company is.

Short-Term Solvency
Long-Term Solvency
Positive Net Debt
Average D/E
37/100
Solvency
Score

Tanvex BioPharma Inc's solvency score is 37/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

Price Targets Summary
Tanvex BioPharma Inc

There are no price targets for Tanvex BioPharma Inc.
Lowest
Price Target
Not Available
Average
Price Target
Not Available
Highest
Price Target
Not Available
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for Tanvex BioPharma Inc?

Click here to dive deeper.

Dividends

Tanvex BioPharma Inc
does not pay dividends
Shareholder Yield

Current shareholder yield for Tanvex BioPharma Inc is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Profile

Tanvex BioPharma Inc Logo
Tanvex BioPharma Inc

Country

Cayman Islands

Industry

Biotechnology

Market Cap

11.2B TWD

Dividend Yield

0%

Description

Tanvex BioPharma, Inc. operates as clinical stage company, which engages in the research and development, production, and sale of pharmaceutical products. The firm is also engaged in areas of strain and cell-line development in both microbial and mammalian systems, cell culture, protein purification, process scale-up, drug substance and product manufacturing and warehousing, sales and distribution. The Company’s product pipeline includes Neupogen (TX-01), TX-05, TX-04, TX-16, TX-52, and others. The firm offers a vertically integrated manufacturing platform for biopharmaceuticals. By controlling the entire process from research and development (R&D) and cell-line development. The firm is developing and delivering biologic and biosimilar drugs to the people.

Contact

George Town
Floor 4, Willow House, Cricket Square, P O BOX 2804
www.tanvex.com

IPO

2015-08-13

Employees

-

Officers

Chief Executive Officer
Mr. Stephen Lam
Founder & Honorary Chairman
Dr. Allen Y. Chao Ph.D.
Chief Financial Officer
Wen Chung Yeh
VP of Finance Director of Ops. Mgmt., Corporate Governance Officer & Chief Internal Auditor
Val Chen
Accounting Officer
Mr. James Williamson
Chief Technology Officer
Mr. Zheng Xia
Show More
Director of Sales & Marketing
Linda Grillo
Secretary
Hsun-Chiang Hsieh
Show Less

See Also

Discover More
What is the Intrinsic Value of one Tanvex BioPharma Inc stock?

The intrinsic value of one Tanvex BioPharma Inc stock under the Base Case scenario is 1.61 TWD.

Is Tanvex BioPharma Inc stock undervalued or overvalued?

Compared to the current market price of 68.1 TWD, Tanvex BioPharma Inc is Overvalued by 98%.

Back to Top